期刊
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
卷 44, 期 1, 页码 155-161出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10863-012-9421-8
关键词
Saccharomyces cerevisiae; 3-bromopyruvate; Multidrug resistance; Transport; Glutathione; Gleevec; Anti-cancer chemotherapy
资金
- Ministry of Science and Higher Education (Poland)
- NIH [CA10951]
We have investigated the cytotoxicity in Saccharomyces cerevisiae of the novel antitumor agent 3-bromopyruvate (3-BP). 3-BP enters the yeast cells through the lactate/pyruvate H+ symporter Jen1p and inhibits cell growth at minimal inhibitory concentration of 1.8 mM when grown on non-glucose conditions. It is not submitted to the efflux pumps conferring Pleiotropic Drug Resistance in yeast. Yeast growth is more sensitive to 3-BP than Gleevec (Imatinib methanesulfonate) which in contrast to 3-BP is submitted to the PDR network of efflux pumps. The sensitivity of yeast to 3-BP is increased considerably by mutations or chemical treatment by buthionine sulfoximine that decrease the intracellular concentration of glutathione.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据